{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) will be the maximum dose at which fewer than one-third of patients experience dose limiting toxicities.","groups":[{"description":"Patients with recurrent or refractory solid tumors, including CNS tumors and lymphoma, receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan IV over 90 minutes on days 8-12 of cycle 1.","id":"OG000","title":"Treatment (Pevonedistat, Temozolomide, Irinotecan)"}],"paramType":"NUMBER","populationDescription":"All Part A patients","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"MTD/RP2D of Pevonedistat in Combination With Irinotecan and Temozolomide","type":"PRIMARY","unitOfMeasure":"mg/m^2"}